75.19

6.77% -5.46

After Hours: 74.70 -0.49 -0.65%

10 X Genomics Inc (TXG)

Overview News Price History Option Chain Financials Discussions Forecast

10 X Genomics Inc stock is traded at $75.19, with a volume of 4.07M. It is down -6.77% in the last 24 hours and up +9.62% over the past month. 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Previous Close:

$80.65

Open:

$79.18

24h Volume:

4.07M

Relative Volume:

0.84

Market Cap:

$9.80B

Revenue:

$638.78M

Net Income/Loss:

$-22.66M

P/E Ratio:

-431.14

EPS:

-0.1744

Net Cash Flow:

$122.18M

1W Performance:

-23.07%

1M Performance:

+9.62%

6M Performance:

+223.12%

1Y Performance:

+555.54%

1-Day Range:

$71.61

$80.47

1-Week Range:

$70.94

$102.81

52-Week Range:

$11.16

$102.81

10 X Genomics Inc Stock (TXG) Company Profile

Name

10 X Genomics Inc

Sector

Healthcare (1051)

Industry

Medical Devices (143)

Phone

(925) 401-7300

Address

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Employee

1,178

Twitter

@10xgenomics

Next Earnings Date

2026-11-05

Latest SEC Filings

TXG's Discussions on Twitter

Compare TXG vs ABT, MDT, SYK, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TXG 10 X Genomics Inc	75.19	9.80B	638.78M	-22.66M	122.18M	-0.1744
ABT Abbott Laboratories	101.82	176.19B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	91.93	117.59B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	282.60	108.40B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	43.84	63.53B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.39	49.80B	6.30B	1.07B	1.09B	1.8406

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-28-26	Initiated	Argus	Buy
Sep-09-26	Resumed	UBS	Neutral
Sep-01-26	Initiated	RBC Capital Mkts	Sector Perform
Mar-31-26	Upgrade	William Blair	Mkt Perform → Outperform
Dec-11-25	Downgrade	Citigroup	Buy → Neutral
Dec-02-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-11-25	Initiated	Piper Sandler	Neutral
Feb-13-25	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-03-24	Initiated	Leerink Partners	Outperform
Jul-22-24	Upgrade	Jefferies	Hold → Buy
Jul-18-24	Downgrade	JP Morgan	Overweight → Neutral
Jul-10-24	Downgrade	Deutsche Bank	Buy → Hold
Jun-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Downgrade	Guggenheim	Buy → Neutral
Jun-03-24	Resumed	Jefferies	Hold
May-01-24	Downgrade	TD Cowen	Buy → Hold
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Dec-12-23	Upgrade	BofA Securities	Underperform → Neutral
Jul-05-23	Resumed	JP Morgan	Overweight
May-10-23	Initiated	Barclays	Overweight
Mar-31-23	Initiated	Stephens	Overweight
Feb-02-23	Initiated	UBS	Neutral
Dec-14-22	Initiated	Deutsche Bank	Buy
Aug-18-22	Downgrade	Goldman	Neutral → Sell
Jul-25-22	Initiated	Canaccord Genuity	Buy
Jul-15-22	Downgrade	BofA Securities	Neutral → Underperform
Jul-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Oct-15-21	Resumed	Cowen	Outperform
Sep-14-21	Downgrade	BofA Securities	Buy → Neutral
Mar-15-21	Initiated	William Blair	Outperform
Dec-02-20	Initiated	Goldman	Neutral
Sep-09-20	Initiated	Morgan Stanley	Overweight
Jul-10-20	Initiated	Stifel	Buy
Mar-05-20	Initiated	Guggenheim	Buy
Jan-07-20	Initiated	Citigroup	Buy
Oct-07-19	Initiated	BofA/Merrill	Buy
Oct-07-19	Initiated	Cowen	Outperform
Oct-07-19	Initiated	JP Morgan	Overweight
Sep-24-19	Initiated	Evercore ISI	Outperform

View All

10 X Genomics Inc Stock (TXG) Latest News

Oct 08, 2026

10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research - Zacks Investment Research

Oct 08, 2026

Oct 07, 2026

ARK and Catherine D. Wood report ownership above 5% in 10x Genomics (TXG). - Stock Titan

Oct 07, 2026

Oct 06, 2026

Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.

Oct 06, 2026

Sep 30, 2026

10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises - Zacks Investment Research

Sep 30, 2026

Sep 24, 2026

10x genomics director Shehnaaz Suliman sells $464,667 in stock - Investing.com

Sep 24, 2026

Form 4 10X Genomics Inc For: 24 September By Investing.com - Investing.com India

Sep 24, 2026

10x genomics director Shehnaaz Suliman sells $464,667 in stock By Investing.com - Investing.com Canada

Sep 24, 2026

Form 4 10X Genomics Inc For: 24 September By Investing.com - Investing.com UK

Sep 24, 2026

Under a trading plan, a 10x Genomics (TXG) director sells 5,723 shares in five transactions. - Stock Titan

Sep 24, 2026

At $77.75 to $82.53 a share, 10x Genomics (TXG) CEO made five sales under a trading plan. - Stock Titan

Sep 24, 2026

Sep 22, 2026

5,723 10x Genomics (NASDAQ: TXG) shares set for Rule 144 sale - Stock Titan

Sep 22, 2026

Sep 12, 2026

Korea's Lunit announces collaboration with 10x Genomics for AI-enabled pathology analysis of cancer - BioSpectrum Asia

Sep 12, 2026

Moderna, 10x Genomics, Oscar Health, and Novavax Shares Are Soaring, What You Need To Know - Yahoo Finance

Sep 12, 2026

Sep 11, 2026

10x Genomics (TXG) CFO Adam Taich Sells 46,388 Shares - GuruFocus

Sep 11, 2026

10x genomics CFO Adam Taich disposes of $2.99 million in company stock - Investing.com Nigeria

Sep 11, 2026

10x genomics CFO Adam Taich disposes of $2.99 million in company stock - Investing.com

Sep 11, 2026